Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 3/20 | 0.36 |
| ▸ | TNKS | O95271 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19984831 | 0.76 | LRRK2 (0.35) | TNKSPARP1PARP2ALDH1A1 | |
| SCHEMBL19866357 | 0.72 | CD274 (0.52) | — | |
| SCHEMBL18078725 | 0.72 | CD274 (0.52) | — | |
| SCHEMBL19984824 | 0.70 | HDAC6 (0.34) | — | |
| SCHEMBL19984850 | 0.69 | HDAC6 (0.40) | MAPT | |
| SCHEMBL19973940 | 0.66 | MAPK1 (0.33) | — | |
| SCHEMBL19973939 | 0.66 | MAPK1 (0.33) | — | |
| SCHEMBL19984980 | 0.62 | PIEZO1 (0.38) | TNKSPARP1PARP2MAPTALDH1A1 | |
| SCHEMBL19984811 | 0.61 | KDM4E (0.43) | L3MBTL1ALDH1A1 | |
| SCHEMBL13269916 | 0.60 | TRHR (0.48) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018051255-A1 | CYCLIC SUBSTITUTED-1,3,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-22 | — | — | WO | disclosed |